Gentamicin for RDEB
Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense Mutations
Sponsor: University of Southern California
Listed as NCT03012191, this PHASE1/PHASE2 trial focuses on Recessive Dystrophic Epidermolysis Bullosa and remains completed. Sponsored by University of Southern California, it has been updated 11 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
May 2019 — Aug 2019 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Feb 2019 — May 2019 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Southern California
For direct contact, visit the study record on ClinicalTrials.gov .